The CA-125 to CEA ratio is occasionally taken before starting neoadjuvant chemotherapy to confirm the histology of the ovarian cancer along with biopsy results (The National Comprehensive Cancer Network [NCCN], 2018b). This evidence concerns the gene MUC16 and ovarian carcinoma.